source
- Male contraception startup closes $92.5M Series B; Novartis bets on actinium💸 Funding male contraception: Contraline closed a $92.5 million Series B financing to support a Phase 3 study of a male contraceptive dubbed NES/T. The daily treatment is a gel rubbed on the shoul…Endpoints · 1mo ago↗ source
- Travere pays Everest $112M upfront to grow rare kidney disease pipelineTravere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…Endpoints · 1mo ago↗ source
- Legend Biotech shares first in vivo CAR-T data, its next act after CarvyktiLegend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-initia…